Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives Average Recommendation of “Moderate Buy” from Brokerages

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $18.00.

Several research firms have weighed in on TVRD. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday, July 8th. UBS Group raised shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price target for the company in a research note on Wednesday, July 8th. BTIG Research lowered their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. HC Wainwright began coverage on Tvardi Therapeutics in a research report on Monday, June 8th. They set a “buy” rating and a $9.00 price target on the stock. Finally, Piper Sandler upgraded Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a report on Wednesday, July 8th.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ TVRD opened at $1.62 on Friday. The stock has a market cap of $21.61 million, a PE ratio of -0.58 and a beta of 0.32. Tvardi Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $43.65. The stock has a fifty day moving average of $2.13 and a 200-day moving average of $2.84.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, sell-side analysts predict that Tvardi Therapeutics will post -2.35 EPS for the current year.

Institutional Trading of Tvardi Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Tvardi Therapeutics during the 2nd quarter valued at approximately $181,000. Susquehanna International Group LLP purchased a new position in shares of Tvardi Therapeutics in the second quarter worth $63,000. Finally, GSA Capital Partners LLP purchased a new position in shares of Tvardi Therapeutics in the second quarter worth $34,000. Institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s approach is designed to address tumor growth, immune suppression and resistance to existing therapies by selectively targeting STAT3, a protein involved in cancer progression.

Tvardi’s lead product candidate is TTI-101, an orally administered small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors.